Mineralocorticoid Receptor Antagonists in CKD: In Need of a Few Large Trials

Affiliations

¹ Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Canada; Chronic Disease Innovation Center, Winnipeg, Canada.
² Department of Medicine, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada; Population Health Research Institute, Hamilton Health Sciences / McMaster University, Hamilton, Canada. Electronic address: lastwalsh1975@gmail.com.

Comment

David Collister et al. Am J Kidney Dis. 2021 May.

. 2021 May;77(5):813-815.

doi: 10.1053/j.ajkd.2020.11.020. Epub 2021 Jan 5.

¹ Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Canada; Chronic Disease Innovation Center, Winnipeg, Canada.
² Department of Medicine, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada; Population Health Research Institute, Hamilton Health Sciences / McMaster University, Hamilton, Canada. Electronic address: lastwalsh1975@gmail.com.

No abstract available

Comment on

Aldosterone Antagonists in Addition to Renin Angiotensin System Antagonists for Preventing the Progression of CKD: Editorial Summary of a Cochrane Review.
Chung EYM, Strippoli GFM. Chung EYM, et al. Am J Kidney Dis. 2021 May;77(5):810-812. doi: 10.1053/j.ajkd.2020.11.019. Epub 2021 Jan 5. Am J Kidney Dis. 2021. PMID: 33418014 No abstract available.